Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR:Fc) in rheumatoid arthritis

BACKGROUND: Tumor necrosis factor (TNF) is the dominant mediator of the cytokine cascade that causes inflammation and joint destruction in rheumatoid arthritis. A new class of agents under investigation, the biologic TNF inhibitors, inhibits the activity of TNF. Recombinant human TNF receptor p75 Fc fusion protein (TNFR:Fc; Enbrel) blocks the activity of the cytokine TNF. The preclinical, Phase I, and Phase II data of TNFR:Fc in rheumatoid arthritis are reviewed in this article. METHODS: All available data on TNFR:Fc in rheumatoid arthritis were reviewed. These data included published literature and data on file at the manufacturer. RESULTS: TNFR:Fc has been effective in many models of inflammation, including animal models of rheumatoid arthritis and in clinical rheumatoid arthritis trials. Conclusions from a study with TNFR "knockout" mice (genetically altered mice incapable of producing TNFR proteins) demonstrated that p75 TNFR is a natural antagonist of TNF-mediated inflammation. A placebo-controlled, dose-escalation, Phase I trial evaluated the safety and efficacy of TNFR:Fc in patients with rheumatoid arthritis. There were no serious adverse effects reported. A Phase II, randomized, double-blind, placebo-controlled trial evaluated 180 patients with active rheumatoid arthritis whose previous therapy had failed. A dose-response relationship was observed in the number of tender and swollen joints; patients who received the highest dose (16 mg/m2) of TNFR:Fc had the greatest improvement. Treatment was generally well tolerated. TNFR:Fc is nonimmunogenic; no antibodies to TNFR:Fc have been detected thus far in human studies. CONCLUSIONS: Preliminary data indicate that TNFR:Fc is an excellent candidate for future long-term studies in the treatment of rheumatoid arthritis.

This article has been cited by other articles:

				C Plater-Zyberk, L A B Joosten, M M A Helsen, M I Koenders, P A Baeuerle, and W B van den Berg Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor {alpha}-independent mouse model Ann Rheum Dis, May 1, 2009; 68(5): 721 - 728. [Abstract] [Full Text] [PDF]

				J. Wong, V. Korcheva, D. B. Jacoby, and B. E. Magun Proinflammatory responses of human airway cells to ricin involve stress-activated protein kinases and NF-{kappa}B Am J Physiol Lung Cell Mol Physiol, December 1, 2007; 293(6): L1385 - L1394. [Abstract] [Full Text] [PDF]

				C Plater-Zyberk, L A B Joosten, M M A Helsen, J Hepp, P A Baeuerle, and W B van den Berg GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice Ann Rheum Dis, April 1, 2007; 66(4): 452 - 457. [Abstract] [Full Text] [PDF]

				C. Arana-Yi, A. Quintas-Cardama, F. Giles, D. Thomas, A. Carrasco-Yalan, J. Cortes, H. Kantarjian, and S. Verstovsek Advances in the Therapy of Chronic Idiopathic Myelofibrosis Oncologist, September 1, 2006; 11(8): 929 - 943. [Abstract] [Full Text] [PDF]

				C. H. Evans and R. N. Rosier Molecular Biology in Orthopaedics: The Advent of Molecular Orthopaedics J. Bone Joint Surg. Am., November 1, 2005; 87(11): 2550 - 2564. [Abstract] [Full Text] [PDF]

				L. Branen, L. Hovgaard, M. Nitulescu, E. Bengtsson, J. Nilsson, and S. Jovinge Inhibition of Tumor Necrosis Factor-{alpha} Reduces Atherosclerosis in Apolipoprotein E Knockout Mice Arterioscler Thromb Vasc Biol, November 1, 2004; 24(11): 2137 - 2142. [Abstract] [Full Text] [PDF]

				C. S. Foster, F. Tufail, N. K. Waheed, D. Chu, E. Miserocchi, S. Baltatzis, and C. M. Vredeveld Efficacy of Etanercept in Preventing Relapse of Uveitis Controlled by Methotrexate Arch Ophthalmol, April 1, 2003; 121(4): 437 - 440. [Abstract] [Full Text] [PDF]